Work Experience

 
 
 
 
 
2001 – Present
Istanbul

Prof.

Kadir Has University

Department of Bioinformatics and Genetics
 
 
 
 
 
1996 – 2001
Istanbul

Prof.

Marmara University

Department of Chemistry
 
 
 
 
 
1990 – 1996
Istanbul

Assoc. Prof.

Marmara University

Department of Chemistry
 
 
 
 
 
1988 – 1989
Izmir

Asst. Prof. & Assoc. Prof.

Ege University

Department of Chemistry
 
 
 
 
 
1987 – 1988
Illinois

Post Doc

Northwestern University

Department of Chemistry

Advisor: Prof. Richard. B. Silverman

Publications

  1. Umut Salgin Goksen, Sevgi Sarigul, Patrick Bultinck, Wouter Herrebout, Ilknur Dogan, Kemal Yelekci, Gulberk Ucar, Nesrin Gokhan Kelekci, (2019), “Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity”, Chirality, 31, 21-23, https://doi.org/10.1002/chir.23027, (IF:1.833).
  2. Abdullahi Ibrahim Uba, Kemal Yelekçi (2019). Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. Journal of Biomolecular Structure and Dynamics, https://doi.org/10.1080/07391102.2018.1521747. (IF: 3.107)
  3. Augustine S. Samorlu, Kemal Yelekçi, Abdullahi Ibrahim Uba (2019). The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2018.1557559 (IF: 3.107).
  4. Abdullahi Ibrahim Uba, Kemal Yelekçi (2018). Identification of potential isoform- selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. Journal of Biomolecular Structure and Dynamics, 36:12, 3231- 3245. http://doi.org/10.1080/07391102.2017.1384402 (IF: 3.107).
  5. Abdullahi Ibrahim Uba, Kemal Yelekçi (2018). Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6. Computational Biology and Chemistry, 77, 318-330. https://doi.org/10.1016/j.compbiolchem.2018.10.016, (IF: 1.412).
  6. Abdullahi Ibrahim Uba, Kemal Yelekçi (2018). Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: structure-based virtual screening, molecular docking and dynamics simulation studies. Computational Biology and Chemistry, 75: 131-142. https://doi.org/10.1016/j.compbiolchem.2018.05.004. (IF: 1.412).
  7. Göknil Coşkun, Teodora Djikic, Taha Hayal, Nezaket Türkel, Kemal Yelekçi, Fikrettin Şahin, Ş Küçükgüzel, “Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors, Molecules 2018, 23, 1969; 2018 doi:10.3390/molecules23081969, (IF:3.09).
  8. Işıl Çoruh, Özge Çevik, Kemal Yelekçi, Teodora Djikic, Ş Güniz Küçükgüzel Synthesis, anticancer activity, and molecular modeling of etodolac‐thioether derivatives as potent methionine aminopeptidase (type II) inhibitors Archiv der Pharmazie,3-4, 351, 2018. https://doi.org/10.1002/ardp.201700195 (IF:2.29).
  9. Teodora Djikic, Yasmina Martí, Francesca Spyrakis, Thorsten Lau, Paolo Benedetti, Gavin Davey, Patrick Schloss & Kemal Yelekci (2018). Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities, Journal of Biomolecular Structure and Dynamics, DOI: 10.1080⁄07391102.2018.1426044, (IF: 3.107).
  10. Abdullahi Ibrahim UBA, Kemal YELEKÇİ (2017). Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors”, Turk J Biol 41, TÜBİTAK doi:10.3906/biy-1701-26. (IF: 0.651).
  11. S.T. Karadeniz, S.U. Akgul, Y. Ogret, H.S. Ciftci, A. Bayraktar, H. Bakkaloglu, Y. Caliskan, K. Yelekci, A. Turkmen, A.E. Aydin, F.S. Oguz, M. Carin, and F. Aydin, “Corrected Panel-Reactive Antibody Positivity Rates for Hypersensitized Patients in Turkish Population With Calculated Panel-Reactive Antibody Software”, http://dx.doi.org/10.1016/j.transproceed.2017.01.032, Transplantation Proceedings, 49, 445e447 (2017). (IF: 0.806).
  12. Karadeniz, Sedat Tanju; Akgul, Sabahat; Ciftci, Hayriye Senturk; Yelekci, Kemal; et al.“Epitope Based Hla Matching By Using Antibody Reactivity With High Resolution Allele Typing And HLA_match maker Algorithm Based Software”Transplant international, 30 Special Issue: SI Supplement: 2 Pages: 302-302 Meeting Abstract, 2017. (IF: 3.196).
  13. Evranos-Aksoz, Begum; Ucar, Gulberk; Tas, Sadik Taskin; Yelekci, Kemal; et al.“New Human Monoamine Oxidase an Inhibitors with Potential Anti-Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity”, Combinatorial chemistry & high throughput screening, 20 Issue: 6 Pages: 461-473, 2017. (IF: 1.205).
  14. Evranos-Aksoz, Begum; Ucar, Gulberk; Yelekci, Kemal, “Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues” Combinatorial chemistry & high throughput screening, 20, Issue: 6 Pages: 510-521, 2017. (IF: 1.205).
  15. Katarina Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, Kemal Yelekci andJohnB.O.Mitchell. “Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies” http://dx.doi.org/10.3389/fnins.2016.00265. Front. Neurosci., 10 June 2016. (IF: 3.877).
  16. Evranos-Aksöz B, Baysal İ, Yabanoğlu-Çiftçi S, Djikic T, Yelekçi K, Uçar G, Ertan R. “Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.“. Arch Pharm (Weinheim). Oct;348(10):743-56. doi: 10.1002/ardp.201500212. Aug 21, (2015). (IF: 2.288).
  17. F. Pinar Turkmenoglu, İpek Baysal, Samiye Ciftci-Yabanoglu, Kemal Yelekci, Hamdi Temel, Salih Paşa, Nurten Ezer, İhsan Çalış and Gulberk Ucar., “Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol.” Molecules Journal, Apr 23;20(5):7454-73. doi: 10.3390/molecules20057454. (2015). (IF: 3.098).
  18. Malcomson T, Yelekci K, Mar Borrello MT, Ganesan A, Semina E, De Kimpe R, Mangelinckx S, Ramsay RR., “cis-Cyclopropylamines as mechanism-based inhibitors of Monoamine Oxidases”, FEBS Journal, DOI: 10.1111/febs.13260, (2015). (IF: 4.53).
  19. Evranos-Aksöz B, Yabanoğlu-Çiftçi S, Uçar G, Yelekçi K, Ertan R. “Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies.” Bioorg Med Chem Lett. 2014. 1;24(15):3278-84. (DOI: 10.1016/j.bmcl.2014.06.015) (2014). (IF: 2.442).
  20. Kemal Yelekçi, Bahanur Örtmen “De Novo Design of Potent and Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors by a Fragment-Based Approach”, Journal of Pharmaceutical Chemistry, 2014, 1 (4), 68-73.
  21. Kemal Yelekçi, Bora Büyüktürk, Nurdan Kayrak, “In silico identification of novel and selective monoamine oxidase B inhibitors”. J Neural Transm 2013. 120:853–858, (DOI 10.1007/s00702-012-0954-0) (2013). (IF: 2.779).
  22. Umut Salgın-Gökşen, Nesrin Gökhan-Kelekçi, Samiye Yabanoğlu-Çiftçi, Kemal Yelekçi, Gülberk Uçar, “Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives”. J Neural Transm . 2013. 120:883–891, (DOI 10.1007/s00702-013-0968-2) (2013). (IF: 2.779).
  23. Umut Salgın-Gökşen, Samiye Yabanoğlu-Çiftçi, Ayşe Ercan, Kemal Yelekçi, Gülberk Uçar, Nesrin Gökhan-Kelekçi, “Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives”. J Neural Transm, 2013. 120:863–873, (DOI 10.1007/s00702-013-0980-6). (2013). (IF: 2.779).
  24. Safiye Sağ Erdem, Seyhan Türkkan, Kemal Yelekçi, Nesrin Gökhan-Kelekçi, “Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations”. J Neural Transm, 2013. 120:859–862, (DOI 10.1007/s00702-012-0950-4) (2013). (IF: 2.779).
  25. Gamze Bora Tatar, Tenzile Deniz Tokluman, Kemal Yelekçi, Hayat Yurter,“Power of inhibition activity screening and 3D molecular modeling approaches in HDAC 8 inhibitor design”. Turk J Chem, 35. 2011. 861 – 870. (doi:10.3906/kim-1107-34), (2011), (IF: 1.377).
  26. Ebru Demet Akdoğan, Burak Erman, Kemal Yelekçi. “In silico design of novel and highly selective lysine-specific histone demethylase inhibitors”. Turk J Chem 35. 2011. 523-542, (doi:10.3906/kim-1102-985) (2011). (IF: 1.377).
  27. Nesrin Gökhan-Kelekçi, Ö. Özgün Şimşek, Ayşe Ercan, Kemal Yelekçi, Z. Sibel Şahin Şamil Işık, Gülberk Uçar, A. Altan Bilgin. “Synthesis and molecular modeling of some novel hexahydroindazole derivatives as “potent monoamine oxidase inhibitors”. Bioorganic & Medicinal Chemistry. 2009, 17(4), 5219-5228. (2009). (IF: 2.881).
  28. Gamze Bora-Tatar, Didem Dayangaç-Erden, Ayhan S. Demir, Sevim Dalkar, Kemal Yelekçi, Hayat Erdem-Yurter, “Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies”. Bioorganic & Medicinal Chemistry. 2009. 17(18), 6761-6772. (2009). (IF: 2.881).
  29. Didem Dayangaç-Erden, Gamze Bora, Peruze Ayhan, Çetin Kocaefe, Sevim Dalkara, Kemal Yelekçi, Ayhan S. Demir, Hayat Erdem-Yurter, “Histone Deacetylase Inhibition Activity and Molecular Docking of (E )-Resveratrol: its Therapeutic Potential in Spinal Muscular Atrophy”. Chemical Biology & Drug Design. 2009, 37(3), 355-364. (2009). (IF: 2.328).
  30. Nesrin Gökhan-Kelekçi, Semra Koyunoğlu, Samiye Yabanoğlu, Kemal Yelekçi, Özen Özgen, Gulberk Uçar, Kevser Erol, Engin Kendi, Akgul Yeşilada,”New Pyrazoline Bearing 4(3H)-quinazolinone Inhibitors of Monoamine Oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity“. Bioorganic & MedicinalChemistry. 2009. 17(2), 675-689. (IF: 2.881).
  31. Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties (ΔG and Ki)”. Journal of Neural Transmission, 2007.114: 725-732. (2007). (IF: 2.779).
  32. Kemal Yelekçi, S. Erdem, Ö. Karahan, F. Uyar,“Synthesis and Thermal Reactions of -Acetoxy-2,6,6-Trimethylbicyclo[3.1.0] hexane: Elucidation of the Mechanism of the Reaction with Coputational Approach”, Journal of Molecular Structure: THEOCHEM, 814 (2007) 61-73. (IF: 1.371).
  33. Yelekci K, Erdem SS , “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo[3.1.0]hexane: Theoretical elucidation of the mechanism”, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 234 Meeting Abstract: 326-COMP Published: AUG 19 2007.
  34. Yelekci K, Bora G, Dayangac-Erden D, et al.“COMP 297-Experimental and molecular docking simulation studies of Histone deacetylases (HDACs) enzyme inhibitors”, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 234 Meeting Abstract: 297-COMP Published: AUG 19 2007.
  35. Yelekci, K, Dayangac-Erden D, Ayhan P, Bora G, et al.“MEDI 333-Histone deacetylase inhibition activity of resveratrol and its analogs”, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 234 Meeting Abstract: 333-MEDI Published: AUG 19 2007.
  36. Safiye Sağ Erdem, Özlem Karahan, İbrahim Yıldız and Kemal Yelekçi .“A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism”. Organic & Biomolecular Chemistry, 2006, 4, 646-658. (2006). (This article was made the cover of this journal.) (IF: 3.423).
  37. Mustafa Toprakçı, Kemal Yelekçi. “Docking studies on Monoamine Oxidase-B inhibitors: estimation of inhibition constants (Ki) of a series of experimentally tested compounds”. Bioorganic & Medicinal Chemistry Letters, 15. 2005. 4438-4446. (2005). (IF: 2.442).
  38. S. S. Erdem; K. Yelekçi,“Computer Modeling of Oxygen Containing Heptylamines as Monoamine Oxidase Inactivators” Journal of Molecular Structure (Theochem) 572 (2001), 97-106. (IF: 1.371).
  39. K. Yelekçi; R.B. Silverman “Effect of the Locus of the Oxygen Atom in Amino Ethers on The Inactivation of Monoamine Oxidase B”. J. Enzyme Inhibition. 1998, 13, 31-39. (1998). (IF: 1.086).
  40. V.J. Drose; J.C.G. Woo; W.P.Hawe; B.M. Hoffman; R:B: Silverman; K. Yelekçi “Observation of a Flavin Semiquinone in the Resting State of Monoamine Oxidase by Electron Paramagnetic resonance and Electron Nuclear Double Resonance”. Biochemistry 1996, 35, 11085-11091. (1996). (IF: 2.997).
  41. K.Yelekçi, “Synthesis of 1-Aminocyclobutane Derivates”Turkish, J.Chem. 1992, 16(1), 18-28. (IF: 1.377).
  42. K.Yelekçi; X.Lu; R.B.Silverman, “Electron Spin resonance Studies of Monoamine Oxidase B. First Direct Evidence for a Substrate Radical Intermediate”, J. Am.Chem.Soc. 1989,111,1338-1340. (IF: 14.357).
  43. W.D. Huntsman; J.P.Chen; K.Yelekçi; T.K.Yin; L.J.Zhang, “Thermal Aromatization of Alkylidenecyclopentenes and Related Hydrocarbons “J. Org. Chem.1988,53,4357-4363. (IF: 4.805).
  44. Yelekçi, K.; H. Evliya.“Isolation and identification of 7-tricosanol from the fruits of Melia azedarach L. tree”, Doğa Bilim Dergisi, Temel Bilim. volume 6, 1982, 45-51.
  45. Yelekçi, K.; Acımış, M.; Soran, H., 1981. “The effect of the extract obtained from the beries of Melia azedarach L. To pine catterpillar (Thaumetopoea Pityocampa Schiff, Lepidoptera: Thaumetopoeidae), Doğa Bilim Dergisi, Temel Bilim, volume 5: 69-71.

Recent & Upcoming Talks

  1. Kemal Yelekçi, Abdullahi I. Uba, “Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors””, VII Serbian Congress of Pharmacy, October 10‐14, 2018, Belgrade, Serbia.
  2. Kemal Yelekçi, Abdullahi I. UBA, “In Silico Modeling of Human Dopamine Transporter”, The International Symposium on Health Informatics and Bioinformatics, (HIBIT), October 25, 2018. Antalya, TURKEY.
  3. Kemal Yelekçi, Abdullahi I. Uba, “In silico modeling of histon deacetyase enzyme and design of novel inhibitors Computational Chemistry: Application of Molecular Dynamics Simulation and Docking Approaches in Drug Design”. Turkey,Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, 21.03.2018.
  4. Kemal Yelekci, Abdullah İbrahim Uba, The search for potential selective inhibitors of human histone deacetylase 6 via pharmacophore-based virtual screening. European Cooperation in Science and Technology (COST) Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, Institut Pasteur, 15th February, 2018, Paris, FRANCE.
  5. Abdullahi İbrahim Uba, Kemal Yelekci. Molecular modelling studies on the recently-solved crystal structure of human histone deacetylase 6 catalytic domain 2 complexed with known inhibitors and the design of potential inhibitors for cancer therapy. 5th Multithematic Biomedical Congress (IMBMC), European University, Cyprus 2nd-4th November, 2017, Nicosia, CYPRUS (GREEK CYPRUS)
  6. Kemal Yelekçi, “In silico identification of Isoform-Selective HDAC Inhibitors”, EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portugal, September, 2017.
  7. Kemal Yelekci, Teodora Djikic, “In silico Modeling of Dopamine Transporter and Design of Novel Neuroprotective Agents”, 252nd ACS National Meeting in Philadelphia, PA, USA, August 21, 2016.
  8. Yelekçi, K. ve Djikic, T. “In Silico Modeling of Human Dopamine Transporter and Design of Novel Inhibitors.” 51st International Conference on Medicinal Chemistry, 01-03.07.2015, Avignon, France.
  9. Yelekçi, K. 2015. “Molecular Docking Studies on Hydroxamic Acid Derivatives as Potential Anticancer Agents via Histone.” COST-EPIGEN Meeting, October 28, 2015, Budapest.
  10. Yelekçi, K. ve Connaly, J. “Homology Modeling of the Human Dopamine Transporter (Hdat): The Elucidation of the Binding Site.” Conference Proceedings EU COST Action CM1103, 8-10 October, 2014, Bordeaux, France.
  11. Rona R. Ramsay, Thomas Malcomson, A. Ganesan, Sven Mangelinckx, Kemal Yelekci, “Cylopropylamine drugs for LSD1 and MAO: Inactivation of MAO”, 18th International Symposium on Flavins and Flavoproteins, July 27- August 1, 2014, THAILAND.
  12. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan, “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
  13. Ucar, G; Evranos-Aksoz, B; Yabanoglu-Ciftci, S; Yelekci, Kemal, “Design and synthesis of novel 2-pyrazoline analogues and their hMAO inhibitory activities, 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, : Berlin, GERMANY, JUL 04-09, 2015.
  14. Evranos-Aksoz, B.; Yabanoglu-Ciftci, S.; Ucar, G; Kemal Yelekçi. “Synthesis and screening of hMAO inhibitory activities of some new 2-pyrazoline and hydrazone derivatives”, FEBS EMBO 2014 Conference Location: Paris, FRANCE Date: AUG 30-SEP 04, 2014.
  15. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan ,. “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
  16. Kemal Yelekçi, “Novel Synthesis and Molecular Modeling of 3-Substituted Aryl-5-(2-Furanyl)-4,5-Dihydro-(1H)-Pyrazol.” Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases: Dissecting and Modulating Complex Function in the Monoaminergic Systems of the Brain, 22-24.04.2014, Bratislava/Slovakya.
  17. Kemal Yelekçi, “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and Its Practical Application.” Program of Training School COST Action CM1103, 09-13.09.2013, Istanbul.
  18. Kemal Yelekçi, “In Silico Design of Novel and Selective Neuronal Nitric Oxide Synthase (Nnos) Inhibitors.” CM1103 Action Conference in Malta: Interdisciplinary Chemical Approaches, 22-25.11.2013, Valletta, Malta.
  19. Kemal YELEKÇİ, A. Bora BÜYÜKTÜRK, Nurdan KAYRAK, Serkan Altuntaş, “In silico design of novel and highly selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2013 RICT- Drug Discovery and Selection, When Chemical Biology meets Drug Design, Nice, France, July 3-5, 2013.
  20. Kemal Yelekci, (Keynote Speaker). “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and its practical application” Summer School: From Computational Enzymology towards Molecular Docking Venue: Main Lecture roomat The National Institute of Chemistry, Ljubljana/Slovenia. May 31, 2013.
  21. Kemal Yelekçi, (invited speaker), “Design of selective monoamine oxidase B inhibitors using saffinamide as a scaffold”, CM1103 Action WG Meeting 24-26 November 2012 Madrid, Spain.
  22. Kemal Yelekci, “In silico design of novel and highly selective monoamine oxidase B inhibitors”, 16-18 july: 15th Amine Oxidase Congress 2012, Toulouse, France.
  23. Kemal Yelekçi, “De novo design of lysine specific histon demethylase (LSD1) inhibitors”, Silverman Symposium (tribute to Prof Richard B. Silverman’s 65th birth day), May 13, 2011, Northwestern University, Evanston, Chicago.
  24. Kemal Yelekçi, “Analysis of monoamine oxidase A and B active sites: evaluation of de novo designed pyrazoline derivatives and pharmacophore generation” The 14th Biennial International Amine Oxidase Workshop, University of Alberta, Edmonton, CANADA, July 18th-21at, 2010.
  25. Kemal Yelekci, “Methods and solutions for lead discovery and optimization, structure and fragment-based design, transmembrane protein analysis, and enzyme modeling”, Workshop European DS Pharmacophore Meeting, 1-3 July 2009, Romainville, Paris, FRANCE.
  26. Kemal Yelekçi, Nesrin Gökhan-Kelekci, Samiye Yabanoğlu, Gülberk Uçar, “Design and Biological Evaluation of New Pyrazoline Bearing 4(3H)-Quinazolinone Inhibitors of Monoamine Oxidase A and B: Binding Mode Studies Performed Through Docking Procedures”, 13th International Amine Oxidase and Related Diseases Workshop ,Century HuatianHotel, Beijing, China, October 11 – 15, 2008.
  27. Kemal Yelekci, “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo [3.1.0] hexane: Theoretical elucidation of the mechanism”234th ACS National Meeting, Boston, MA, (USA), August 19-23, 2007.
  28. Kemal Yelekçi, Mustafa Toprakçı, “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties”, 232nd ACS National Meeting, San Francisco, CA, USA, September 10-14, 2006,
  29. Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites”, “12th International Amine Oxidase Workshop “, University of Erasmus, August 30, 2006, Rotterdam, Nederland.
  30. M. Toprakçı, K. Yelekçi, “Binding affinity prediction of oxygen containing heptylamines as monoamine oxidase inactivators by molecular dynamics calculations.”11th Amine Oxidase Workshop, University of St. Andrews, July 25, 2004, Scotland.
  31. M. Toprakçı, K. Yelekçi, “Molecular Mechanics Analysıs of Binding Affinties of two Putative Ligands for Monoamine Oxidase-B Enzyme.”, 10th Amine Oxidase Workshop, University of Kadir Has, August 25, 2002, Istanbul, TURKEY.
  32. Kemal Yelekçi, R.B. Silverman, S. S. Erdem, “Inductive Effect of a Heteroatom Containing Heptylamine Analogues on MAO B.” 9th International Amine Oxidase Workshop, The Millennium Meeting, Barcelona, July 9th-12th, 2000.
  33. Kemal Yelekçi, NATO Advanced Study Institute on “Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds” Oxidation Mechanism of Monoamine Oxidase.” August 27-September 7,1989 Çeşme, İZMİR-TURKEY
  34. Kemal Yelekçi, American Chemical Society 191st National Meeting, New York, NY April 13-18, 1986.

Books

  1. Katırına Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, Kemal Yelekci and John B. O. Mitchell, Computational approaches for multi-target drug design Drug Design for CNS Diseases: Screening Methodologies, Book Chapter, pp. 18-37, Ramsay, R. R., Di Giovanni, G., eds. (2017). Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases. Lausanne: Frontiers Media. doi: 10.3389⁄978-2-88945-123-4. (Book Chapter).
  2. Kemal Yelekçi, Turhan Altınata “Modern University Chemistry Problems“, (Turkish) Çağlayan Kitapevi, Beyoğlu, İstanbul, 1989. (ISBN 975-436-002-2).
  3. Kemal Yelekçi “Modern Nuclear Magnetic Resonance Spectroscopy and application”, (Turkish) Marmara Üniversitesi Teknik Eğtitim.Fak. Matbaası, İstanbul,1991, 362 pages. (ISBN 975-400-064-6)

Projects

  1. TÜBİTAK-1001-SBAG 218S549 “Molecular modeling, synthesis, and potential anticancer activity of heteroaryl sulfanyl acetamide derivatives through apoptosis, angiogenesis and mPGES-1enzyme (Microsomal prostaglandin E2 synthase1) inhibitor.” Researcher. Budget: 716,000 TL (2019-2022).
  2. TÜBİTAK-1003. 2015S009 “Development of Novel Synthetic Agents for Prostate Cancer Treatment.” Researcher. Budget: 2,817,996 TL (2016-2020)
  3. COST Action. (CM1406) “Epigenetic Chemical Biology (EPICHEM)”. Researcher. Budget: ~650,000 Euro (2015-2018)
  4. FP7. Marie Curie Initial Training Networks (ITN). Call: FP7-PEOPLE-2013-ITN. Project ID: 608381. “Training in Neurodegeneration, Therapeutics Intervention & Neurorepair – TINTIN”. Researcher. Budget: 3,817,235 Euro (2013-2017)
  5. ISTKA. “Establishment of Networking between Academia and Drug Companies and organization of a new Technology Center for a novel drug discovery, development and knowledge sharing”. Researcher. Budget: 1,788,000 TL (2012-2013)
  6. COST Action CM1103. “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”. Researcher. Budget: 550,000 Euro (2011-2015)
  7. TÜBİTAK-TBAG 211T100. “In Silico Design of Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors in Order to Prevent Neurodegenerative Diseases”. Project Director. Budget: 19,350 TL (2012-2013)
  8. TÜBİTAK 1007 (105G01), “Drug research and development for hereditary diseases caused by erroneous RNA splicing”. Researcher. Budget: 1,577,827 TL (2006-2009)
  9. FP6-MOBILITY. “Characterization of Mitochondrial Proteins in Brain”, Researcher. Budget: 1,199,583 Euro (2006-2010).
  10. TÜBİTAK-TBAG 108T232 “Design of new pyrazoline derivatives using molecular modelling; synthesis and determination of their inhibition kinetics by computational and experimental techniques”. Project Director. Budget: 298,000 TL (2008-2010)
  11. TÜBİTAK-TBAG 1332 (194T033) “A novel synthetic method for 3,4-dihydroxyphenylalanin (L-DOPA) using baker’s yeast (Saccharomyces Cerevisiae)”, Project Director. (2000-2004)
  12. TÜBİTAK-TBAG 520 Extraction of the insect repellent agents of “Melia Azedarach L” tree, and application to cotton pest. Researcher. (1983-1986).

Conferences

  1. Conference Organizer/Chair:

    1. 10th International Amine Oxidase Workshop August 24, 2002 (Istanbul, Turkey), Organizer and Chair.
    2. 13th International Amine Oxidase and Related Diseases Workshop, Beijing, China, October 11 – 15, 2008, Program Committee.
    3. Training School COST Action CM1103, October 8, 2013, Istanbul. Organizer.
    4. EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portugal, September, 2017. Program Committee.
    5. Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, Istanbul, 2017. Organizer.
    6. Training School Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, 21.03.2018. Istanbul. Organizer.
    7. The International Symposium on Health Informatics and Bioinformatics, (HIBIT),. October 24, 2018. Antalya, TURKEY. Program Committee.

  2. Selected International Conferences Attended:

    1. Kemal Yelekçi, Abdullahi I. Uba, “Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors””, VII Serbian Congress of Pharmacy, October 10‐14, 2018, Belgrade, Serbia.
    2. Kemal Yelekçi, Abdullahi I. UBA, “In Silico Modeling of Human Dopamine Transporter”, The International Symposium on Health Informatics and Bioinformatics, (HIBIT), October 25, 2018. Antalya, TURKEY.
    3. Kemal Yelekçi, Abdullahi I. Uba, “In silico modeling of histon deacetyase enzyme and design of novel inhibitors Computational Chemistry: Application of Molecular Dynamics Simulation and Docking Approaches in Drug Design”. Turkey,Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, 21.03.2018.
    4. Kemal Yelekci, Abdullah İbrahim Uba, The search for potential selective inhibitors of human histone deacetylase 6 via pharmacophore-based virtual screening. European Cooperation in Science and Technology (COST) Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, Institut Pasteur, 15th February, 2018, Paris, FRANCE.
    5. Abdullahi İbrahim Uba, Kemal Yelekci. Molecular modelling studies on the recently-solved crystal structure of human histone deacetylase 6 catalytic domain 2 complexed with known inhibitors and the design of potential inhibitors for cancer therapy. 5th Multithematic Biomedical Congress (IMBMC), European University, Cyprus 2nd-4th November, 2017, Nicosia, CYPRUS (GREEK CYPRUS)
    6. Kemal Yelekçi, “In silico identification of Isoform-Selective HDAC Inhibitors”, EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portugal, September, 2017.
    7. Kemal Yelekci, Teodora Djikic, “In silico Modeling of Dopamine Transporter and Design of Novel Neuroprotective Agents”, 252nd ACS National Meeting in Philadelphia, PA, USA, August 21, 2016.
    8. Yelekçi, K. ve Djikic, T. “In Silico Modeling of Human Dopamine Transporter and Design of Novel Inhibitors.” 51st International Conference on Medicinal Chemistry, 01-03.07.2015, Avignon, France.
    9. Yelekçi, K. 2015. “Molecular Docking Studies on Hydroxamic Acid Derivatives as Potential Anticancer Agents via Histone.” COST-EPIGEN Meeting, October 28, 2015, Budapest.
    10. Yelekçi, K. ve Connaly, J. “Homology Modeling of the Human Dopamine Transporter (Hdat): The Elucidation of the Binding Site.” Conference Proceedings EU COST Action CM1103, 8-10 October, 2014, Bordeaux, France.
    11. Rona R. Ramsay, Thomas Malcomson, A. Ganesan, Sven Mangelinckx, Kemal Yelekci, “Cylopropylamine drugs for LSD1 and MAO: Inactivation of MAO”, 18th International Symposium on Flavins and Flavoproteins, July 27- August 1, 2014, THAILAND.
    12. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan, “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
    13. Ucar, G; Evranos-Aksoz, B; Yabanoglu-Ciftci, S; Yelekci, Kemal, “Design and synthesis of novel 2-pyrazoline analogues and their hMAO inhibitory activities, 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, : Berlin, GERMANY, JUL 04-09, 2015.
    14. Evranos-Aksoz, B.; Yabanoglu-Ciftci, S.; Ucar, G; Kemal Yelekçi. “Synthesis and screening of hMAO inhibitory activities of some new 2-pyrazoline and hydrazone derivatives”, FEBS EMBO 2014 Conference Location: Paris, FRANCE Date: AUG 30-SEP 04, 2014.
    15. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan ,. “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
    16. Kemal Yelekçi, “Novel Synthesis and Molecular Modeling of 3-Substituted Aryl-5-(2-Furanyl)-4,5-Dihydro-(1H)-Pyrazol.” Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases: Dissecting and Modulating Complex Function in the Monoaminergic Systems of the Brain, 22-24.04.2014, Bratislava/Slovakya.
    17. Kemal Yelekçi, “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and Its Practical Application.” Program of Training School COST Action CM1103, 09-13.09.2013, Istanbul.
    18. Kemal Yelekçi, “In Silico Design of Novel and Selective Neuronal Nitric Oxide Synthase (Nnos) Inhibitors.” CM1103 Action Conference in Malta: Interdisciplinary Chemical Approaches, 22-25.11.2013, Valletta, Malta.
    19. Kemal YELEKÇİ, A. Bora BÜYÜKTÜRK, Nurdan KAYRAK, Serkan Altuntaş, “In silico design of novel and highly selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2013 RICT- Drug Discovery and Selection, When Chemical Biology meets Drug Design, Nice, France, July 3-5, 2013.
    20. Kemal Yelekci, (Keynote Speaker). “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and its practical application” Summer School: From Computational Enzymology towards Molecular Docking Venue: Main Lecture roomat The National Institute of Chemistry, Ljubljana/Slovenia. May 31, 2013.
    21. Kemal Yelekçi, (invited speaker), “Design of selective monoamine oxidase B inhibitors using saffinamide as a scaffold”, CM1103 Action WG Meeting 24-26 November 2012 Madrid, Spain.
    22. Kemal Yelekci, “In silico design of novel and highly selective monoamine oxidase B inhibitors”, 16-18 july: 15th Amine Oxidase Congress 2012, Toulouse, France.
    23. Kemal Yelekçi, “De novo design of lysine specific histon demethylase (LSD1) inhibitors”, Silverman Symposium (tribute to Prof Richard B. Silverman’s 65th birth day), May 13, 2011, Northwestern University, Evanston, Chicago.
    24. Kemal Yelekçi, “Analysis of monoamine oxidase A and B active sites: evaluation of de novo designed pyrazoline derivatives and pharmacophore generation” The 14th Biennial International Amine Oxidase Workshop, University of Alberta, Edmonton, CANADA, July 18th-21at, 2010.
    25. Kemal Yelekci, “Methods and solutions for lead discovery and optimization, structure and fragment-based design, transmembrane protein analysis, and enzyme modeling”, Workshop European DS Pharmacophore Meeting, 1-3 July 2009, Romainville, Paris, FRANCE.
    26. Kemal Yelekçi, Nesrin Gökhan-Kelekci, Samiye Yabanoğlu, Gülberk Uçar, “Design and Biological Evaluation of New Pyrazoline Bearing 4(3H)-Quinazolinone Inhibitors of Monoamine Oxidase A and B: Binding Mode Studies Performed Through Docking Procedures”, 13th International Amine Oxidase and Related Diseases Workshop ,Century HuatianHotel, Beijing, China, October 11 – 15, 2008.
    27. Kemal Yelekci, “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo [3.1.0] hexane: Theoretical elucidation of the mechanism”234th ACS National Meeting, Boston, MA, (USA), August 19-23, 2007.
    28. Kemal Yelekçi, Mustafa Toprakçı, “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties”, 232nd ACS National Meeting, San Francisco, CA, USA, September 10-14, 2006,
    29. Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites”, “12th International Amine Oxidase Workshop “, University of Erasmus, August 30, 2006, Rotterdam, Nederland.
    30. M. Toprakçı, K. Yelekçi, “Binding affinity prediction of oxygen containing heptylamines as monoamine oxidase inactivators by molecular dynamics calculations.”11th Amine Oxidase Workshop, University of St. Andrews, July 25, 2004, Scotland.
    31. M. Toprakçı, K. Yelekçi, “Molecular Mechanics Analysıs of Binding Affinties of two Putative Ligands for Monoamine Oxidase-B Enzyme.”, 10th Amine Oxidase Workshop, University of Kadir Has, August 25, 2002, Istanbul, TURKEY.
    32. Kemal Yelekçi, R.B. Silverman, S. S. Erdem, “Inductive Effect of a Heteroatom Containing Heptylamine Analogues on MAO B.” 9th International Amine Oxidase Workshop, The Millennium Meeting, Barcelona, July 9th-12th, 2000.
    33. Kemal Yelekçi, NATO Advanced Study Institute on “Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds” Oxidation Mechanism of Monoamine Oxidase.” August 27-September 7,1989 Çeşme, İZMİR-TURKEY
    34. Kemal Yelekçi, American Chemical Society 191st National Meeting, New York, NY April 13-18, 1986.

Research Group

  1. Sedat Tanju Karadeniz (Ph. D) Augmented Virtual-Cross-Match for Donor-Induced Antibody Prediction by Using High Resolution HLA Typing and HLA Epitope Mapping for Better Donor Match
  2. Ammar Elmezayen (Ph. D) Selective and Potent Inhibitors Design for Anticancer Agents via Histone Deacetylase Inhibition using Pharmacophore Modeling
  3. Sarah Boumezber (Ph. D) Designing of Selective and Potential of Neuronal Nitric Oxide Synthase Inhibitors Toward the Prevention Neurodegenerative Disease. Using in Silico Screening Methods
  4. Maryam Muhsin T. Al-Rikabi (M. S.) Molecular modeling of cyclopropyl amine derivatives as inhibitors of lysine specific demethylase 1.
  5. Anas Al Obaidi (M. S.) Development of Selective and Potent Inhibitors for GABA-T enzyme via in silico Screening Methods
  6. Marwah Abd Ali N.Al-Shafeay (M. S.) Selective Inhibitor Design for Lysine Demethylase 1 (LSD1) Enzyme Using Molecular Modeling Techniques
  7. Sarah Raji (M. S.) Developing Dual inhibitors for Monoamine Oxidase B and Acetylcholine Esterase Enzyme for Neuroprotection
  8. Farah Abduljabbar (M. S.) In silico Screening of Potential Agonist for Peroxisome Proliferator Activated Receptor (PPARa/b) to Treat Diabetes Miletus
  9. Osamah Almnezal (M. S.) Computational Approach to DNA/RNA Aptamers Design for Diabetes Mellitus Type 2 (T2DM)
  10. Ali Forat Abdulsattar Algburi (M. S.) Computational Approach to DNA Aptamers Design for Multiple Sclerosis (MS)

Contact

  • 0 212 533 65 32
  • Cibali Mah. Hisaraltı Cad. No:17 Fatih / İSTANBUL 34083
  • Monday 10:00 to 13:00
    Wednesday 09:00 to 10:00
    Otherwise email to book an appointment